Federal documents show he disagreed with conclusions the benefits outweighed the risk of side effects, which are rare.

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

Moderna Inc. said its experimental flu shot met its goal in a late-stage trial, clearing the path for its broader strategy of ...

Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

Moderna’s mRNA flu shot outperforms existing vaccines in Phase 3 trial, showing over 26% greater efficacy—paving the way for ...

Moderna's new flu vaccine, based on the same mRNA technology used in its COVID-19 shot, showed promising results in a major ...

The US Food and Drug Administration’s top vaccine official overrode agency experts in May to recommend against the broad use ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...

Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.